La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

O. Rascol And NotEspagne

List of bibliographic references

Number of relevant bibliographic references: 123.
Ident.Authors (with country if any)Title
000278 K. Dujardin [France] ; N. Auzou [France] ; E. Lhommée [France] ; V. Czernecki [France] ; B. Dubois [France] ; A. Fradet [France] ; D. Maltete [France] ; M. Meyer [France] ; F. Pineau [France] ; E. Schmitt [France] ; F. Sellal [France] ; F. Tison [France] ; T. Vidal [France] ; J-P Azulay [France] ; M-L Welter [France] ; J-C Corvol [France] ; F. Durif [France] ; O. Rascol [France]French consensus procedure for assessing cognitive function in Parkinson's disease.
000932 R A Hauser [États-Unis] ; A H V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche]Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
000D32 P. Péran [France] ; F. Nemmi ; D. Méligne ; D. Cardebat ; A. Peppe ; O. Rascol ; C. Caltagirone ; J F Demonet ; U. SabatiniEffect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
000D94 Stephan Klebe [France, Allemagne] ; Jean-Louis Golmard [France] ; Michael A. Nalls [États-Unis] ; Mohamad Saad [France] ; Andrew B. Singleton [États-Unis] ; Jose M. Bras [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Javier Simon-Sanchez [États-Unis, Pays-Bas] ; Peter Heutink [Pays-Bas] ; Gregor Kuhlenb Umer [Allemagne] ; Rim Charfi [France, Tunisie] ; Christine Klein [Allemagne] ; Johann Hagenah [Allemagne] ; Thomas Gasser [Allemagne] ; Isabel Wurster [Allemagne] ; Suzanne Lesage [France] ; Delia Lorenz [Allemagne] ; Günther Deuschl [Allemagne] ; Franck Durif [France] ; Pierre Pollak [France] ; Philippe Damier [France] ; François Tison [France] ; Alexandra Durr [France] ; Philippe Amouyel [France] ; Jean-Charles Lambert [France] ; Christophe Tzourio [France] ; Cécilia Maubaret [France] ; Fanny Charbonnier-Beaupel [France] ; Khadija Tahiri [France] ; Marie Vidailhet [France] ; Maria Martinez [France] ; Alexis Brice [France] ; Jean-Christophe Corvol [France] ; Yves Agid [France] ; M. Anheim ; A-M Bonnet ; M. Borg ; A. Brice ; E. Broussolle ; J-C Corvol ; Ph. Damier ; A. Destée ; A. Durr ; F. Durif ; S. Klebe ; E. Lohmann ; M. Martinez ; C. Penet ; P. Pollak ; P. Krack ; O. Rascol ; F. Tison ; C. Tranchant ; M. Vérin ; F. Viallet ; Vincent Plagnol ; Jose M. Bras ; Dena G. Hernandez ; Manu Sharma ; Una-Marie Sheerin ; Mohamad Saad ; Javier Sim N-Sánchez ; Claudia Schulte ; Suzanne Lesage ; Sigurlaug Sveinbjörnsd Ttir ; Philippe Amouyel ; Sampath Arepalli ; Gavin Band ; Roger A. Barker ; Céline Bellinguez ; Yoav Ben-Shlomo ; Henk W. Berendse ; Daniela Berg ; Kailash Bhatia ; Rob Ma De Bie ; Alessandro Biffi ; Bas Bloem ; Zoltan Bochdanovits ; Michael Bonin ; Kathrin Brockmann ; Janet Brooks ; David J. Burn ; Gavin Charlesworth ; Honglei Chen ; Patrick F. Chinnery ; Sean Chong ; Carl E. Clarke ; Mark R. Cookson ; J Mark Cooper ; Jean Christophe Corvol ; Carl Counsell ; Philippe Damier ; Jean-François Dartigues ; Panos Deloukas ; David T. Dexter ; Karin D. Van Dijk ; Allissa Dillman ; Frank Durif ; Sarah Edkins ; Jonathan R. Evans ; Thomas Foltynie ; Colin Freeman ; Jianjun Gao ; Michelle Gardner ; Raphael Gibbs ; Alison Goate ; Emma Gray ; Rita Guerreiro ; Mar Gústafsson ; Clare Harris ; Garrett Hellenthal ; Jacobus J. Van Hilten ; Albert Hofman ; Albert Hollenbeck ; Janice Holton ; Michele Hu ; Xuemei Huang ; Heiko Huber ; Gavin Hudson ; Sarah E. Hunt ; Johanna Huttenlocher ; Thomas Illig ; Pálmi V. J Nsson ; Cordelia Langford ; Andrew Lees ; Peter Lichtner ; Patricia Limousin ; Grisel Lopez ; Delia Lorenz ; Alisdair Mcneill ; Catriona Moorby ; Huw Morris ; Karen E. Morrison ; Ese Mudanohwo ; Sean S. O'Sullivan ; Justin Pearson ; Richard Pearson ; Joel S. Perlmutter ; Hjörvar Pétursson ; Matti Pirinen ; Pierre Pollak ; Bart Post ; Simon Potter ; Bernard Ravina ; Tamas Revesz ; Olaf Riess ; Fernando Rivadeneira ; Patrizia Rizzu ; Mina Ryten ; Stephen Sawcer ; Anthony Schapira ; Hans Scheffer ; Karen Shaw ; Ira Shoulson ; Ellen Sidransky ; Rohan De Silva ; Colin Smith ; Chris Ca Spencer ; Hreinn Stefánsson ; Stacy Steinberg ; Joanna D. Stockton ; Amy Strange ; Zhan Su ; Kevin Talbot ; Carlie M. Tanner ; Avazeh Tashakkori-Ghanbaria ; François Tison ; Daniah Trabzuni ; Bryan J. Traynor ; G. Uitterlinden ; Jana Vandrovcova ; Daan Velseboer ; Marie Vidailhet ; Damjan Vukcevic ; Robert Walker ; Bart Van De Warrenburg ; Michael E. Weale ; Mirdhu Wickremaratchi ; Nigel Williams ; Caroline H. Williams-Gray ; Sophie Winder-Rhodes ; Maria Martinez ; Peter Donnelly ; John Hardy ; Peter Heutink ; Alexis Brice ; Thomas Gasser ; Nicholas W. Wood ; Andrew B. SingletonThe Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism
000E25 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche]Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease
000E44 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche]Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease
000F76 P. Peran [France, Italie] ; F. Nemmi [Italie] ; D. Meligne [France] ; D. Cardebat [France] ; A. Peppe [Italie] ; O. Rascol [France] ; C. Caltagirone [Italie] ; J. F. Demonet [Suisse] ; U. Sabatini [Italie]Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: A fMRI study
001089 O. Rascol [France] ; J. Bronzova ; R A Hauser ; A E Lang ; C. Sampaio ; A. Theeuwes ; S V Van De WittePardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
001245 S. Perez-Lloret [France, Argentine] ; L. Nègre-Pagès [France] ; A. Ojero-Senard [France] ; P. Damier ; A. Destée ; F. Tison [France] ; M. Merello [Argentine] ; O. Rascol [France]Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort
001723 O. Rascol [France]Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
001838 Werner Poewe [Autriche] ; O. Rascol [France] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno ; M. Haaksma ; L. Salin ; N. Juhel ; A. H. V. SchapiraExtended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial
001839 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; L. Salin [France] ; N. Juhel [France] ; Werner Poewe [Autriche]Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial
001A08 P. Payoux [France] ; C. Brefel-Courbon ; F. Ory-Magne ; W. Regragui ; C. Thalamas ; S. Balduyck ; F. Durif ; J P Azulay ; F. Tison ; O. Blin ; J P Esquerre ; O. RascolMotor activation in multiple system atrophy and Parkinson disease: a PET study.
001A93 Suzanne Lesage ; Etienne Patin ; Christel Condroyer ; Anne-Louise Leutenegger ; Ebba Lohmann ; Nir Giladi ; Anat Bar-Shira ; Soraya Belarbi ; Nassima Hecham ; Pierre Pollak ; Anne-Marie Ouvrard-Hernandez ; Soraya Bardien ; Jonathan Carr ; Traki Benhassine ; Hiroyuki Tomiyama ; Caroline Pirkevi ; Tarik Hamadouche [Algérie] ; Ccile Cazeneuve [France] ; A. Nazli Basak ; Nobutaka Hattori ; Alexandra Drr [France] ; Meriem Tazir ; Avi Orr-Urtreger ; Lluis Quintana-Murci ; Alexis Brice [France] ; Yves Agid [France] ; A.-M. Bonnet ; M. Borg ; A. Brice ; E. Broussolle ; Ph. Damier ; A. Deste ; A. Drr ; F. Durif ; E. Lohmann ; M. Martinez ; C. Penet ; P. Pollak ; O. Rascol ; F. Tison ; C. Tranchant ; A. Troiano ; M. Vrin ; F. Viallet ; M. VidailhetParkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans
001D14 C. Warren Olanow [États-Unis] ; O. Rascol [France]The delayed-start study in Parkinson disease: Can't satisfy everyone
001D31 P. Payoux [France] ; C. Brefel-Courbon [France] ; F. Ory-Magne [France] ; W. Regragui [France] ; C. Thalamas [France] ; S. Balduyck [France] ; F. Durif [France] ; J. P. Azulay [France] ; F. Tison [France] ; O. Blin [France] ; J. P. Esquerre [France] ; O. Rascol [France]Motor activation in multiple system atrophy and Parkinson disease: A PET study
002363 J. C. Sharma [Royaume-Uni] ; I. N. Ross [Royaume-Uni] ; O. Rascol [France] ; D. Brooks [Royaume-Uni]Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight
002443 O. Rascol [France]Thérapeutiques du stade précoce de la maladie de Parkinson
002698 A. Gerdelat-Mas [France] ; M. Simonetta-Moreau [France] ; C. Thalamas [France] ; F. Ory-Magne [France] ; T. Slaoui [France] ; O. Rascol [France] ; C. Brefel-Courbon [France]Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study
002776 T. Slaoui [France] ; A. Mas-Gerdelat [France] ; F. Ory-Magne [France] ; O. Rascol [France] ; C. Brefel-Courbon [France]La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien
002958 J. J. Ferreira [Portugal] ; K. Desboeuf [France] ; M. Galitzky [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; N. Fabre [France] ; J. Senard [France] ; J. Montastruc [France] ; C. Sampaio [Portugal] ; O. Rascol [France]Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers
002E49 F. Durif [France] ; B. Debilly ; M. Galitzky ; D. Morand ; F. Viallet ; M. Borg ; S. Thobois ; E. Broussolle ; O. RascolClozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.
002F29 P. Pollak [France] ; F. Tison [France] ; O. Rascol [France] ; A. Destée [France] ; J J Péré [France] ; J M Senard [France] ; F. Durif [France] ; I. Bourdeix [France]Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
003031 F. Durif [France] ; B. Debilly [France] ; M. Galitzky [France] ; D. Morand [France] ; F. Viallet [France] ; M. Borg [France] ; S. Thobois [France] ; E. Broussolle [France] ; O. Rascol [France]Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
003081 P. Cintas [France] ; M. Simonetta-Moreau ; F. Ory ; C. Brefel-Courbon ; N. Fabre ; P. Chaynes ; J. Sabatier ; J C Sol ; O. Rascol ; I. Berry ; Y. LazorthesDeep brain stimulation for parkinson's disease: correlation between intraoperative subthalamic nucleus neurophysiology and most effective contacts.
003305 O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L Montastruc[Management of levodopa-induced dyskinesia].
003311 M. Simonetta Moreau [France] ; S. Meunier ; M. Vidailhet ; S. Pol ; M. Galitzky ; O. RascolTransmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease.
003313 O. Rascol [France] ; P. Payoux ; J. Ferreira ; C. Brefel-CourbonThe management of patients with early Parkinson's disease.
003326 Y. Tsuboi [États-Unis] ; M. Baker ; M L Hutton ; R J Uitti ; O. Rascol ; M-B Delisle ; X. Soulages ; J R Murrell ; B. Ghetti ; M. Yasuda ; O. Komure ; S. Kuno ; K. Arima ; N. Sunohara ; T. Kobayashi ; Y. Mizuno ; Z K WszolekClinical and genetic studies of families with the tau N279K mutation (FTDP-17).
003420 J. L. Montastruc [France] ; O. Rascol [France]Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ?
003421 O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France]Prise en charge des dyskinésies par la lévodopa
003464 M. Simonetta Moreau [France] ; S. Meunier [France] ; M. Vidailhet [France] ; S. Pol [France] ; M. Galitzky [France] ; O. Rascol [France]Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease
003568 F. Chollet [France] ; I. Loubinoux ; J. Pariente ; C. Carel ; J F Albucher ; O. Rascol ; B. Guiraud-Chaumeil[Pharmacologic modification of cerebral activity: value of functional neuroimaging].
003570 O. Rascol [France] ; J. Ferreira ; J L Montastruc[Abnormal diurnal somnolence, "sleep attacks" and antiparkinson drugs].
003572 O. Rascol [France] ; N. Fabre ; C. Brefel-Courbon ; J L MontastrucThe pharmacologic treatment of gait ignition failure.
003778 O. Rascol [France] ; J. Ferreira [France, Portugal] ; J.-L. Montastruc [France]Pharmacologie: Somnolence diurne anormale, « attaques de sommeil » et médicaments antiparkinsoniens
003824 O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis]Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease
003828 O. Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
003839 S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France]Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
003864 O. Rascol [France] ; J L Montastruc[Role of dopaminergic agonists].
003869 O. Rascol [France]The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
003872 J J Ferreira [France] ; O. RascolPrevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
003895 Jj Ferreira [France, Portugal] ; M. Galitzky [France] ; Jl Montastruc [France] ; O. Rascol [France]Sleep attacks and Parkinson's disease treatment
003B28 O. Rascol [France] ; J.-L. Montastruc [France]La place des agonistes dopaminergiques
003B58 O. Rascol [France]The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease
003B73 O. Rascol [France]Medical treatment of levodopa-induced dyskinesias
003C01 U. Sabatini [France] ; K. Boulanouar [France, Italie] ; N. Fabre [France] ; F. Martin [France] ; C. Carel [France] ; C. Colonnese [Italie] ; L. Bozzao [Italie] ; I. Berry [France] ; J. L. Montastruc [France] ; F. Chollet [France] ; O. Rascol [France]Cortical motor reorganization in akinetic patients with Parkinson's disease: A functional MRI study
003C16 O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
003C55 O. Rascol [France]Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
003C58 O. Rascol [France] ; C. Brefel-Courbon ; S. Descombes ; J L MontastrucClinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
003C60 M B Delisle [France] ; J R Murrell ; R. Richardson ; J A Trofatter ; O. Rascol ; X. Soulages ; M. Mohr ; P. Calvas ; B. GhettiA mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy.
003E57 C. Brefel-Courbon ; O. RascolScintigraphies cérébrales et syndromes parkinsoniens
003E73 O. Rascol [France]Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques
003F04 C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France]Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease
003F05 O. Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach
003F34 O. Rascol [France] ; O. Blin [France] ; C. Thalamas [France] ; S. Descombes [France] ; C. Soubrouillard [France] ; P. Azulay [France] ; N. Fabre [France] ; F. Viallet [France] ; K. Lafnitzegger [États-Unis] ; S. Wright [États-Unis] ; J. H. Carter [États-Unis] ; J. G. Nutt [États-Unis]ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease
003F35 H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France]A study of salivary secretion in Parkinson's disease
004109 O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France]Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens
004128 C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France]α2-Adrenoceptor antagonists: A new approach to Parkinson's disease?
004134 A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie]The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease
004137 A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie]Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study
004138 O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study
004157 J. L. Montastruc [France] ; M. Pelat [France] ; P. Verwaerde [France] ; C. Brefel-Courbon [France] ; M. A. Tran [France] ; O. Blin [France] ; O. Rascol [France] ; J. M. Senard [France]Fluoxetine in orthostatic hypotension of Parkinson's disease : A clinical and experimental pilot study
004161 C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France]Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
004167 O. Rascol [France] ; U. Sabatini [France, Italie] ; C. Brefel [France] ; N. Fabre [France] ; S. Rai [France] ; J. M. Senard [France] ; P. Celsis [France] ; G. Viallard [France] ; J. L. Montastruc [France] ; F. Chollet [France]Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia
004174 D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni]A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease
004365 J.-L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France]Pharmacologie des médicaments antiparkinsoniens : bilan et perspectives : Maladie de Parkinson
004366 N. Fabre [France] ; C. Brefel-Courbon [France] ; O. Rascol [France]Parkinson « plus » : Mouvements anormaux
004387 O. Rascol [France] ; N. Fabre [France] ; U. Sabatini [Italie]Imagerie fonctionnelle
004391 O. Rascol [France] ; N. Fabre [France] ; J.-L. Montastruc [France]Fluctuations de la réponse à la L-dopa dans la maladie de Parkinson : Maladie de Parkinson - 2e partie
004403 C. Soubrouillard [France] ; C. Lombardo [France] ; O. Rascol [France] ; B. Bruguerolle [France] ; O. Blin [France]Agonistes dopaminergiques centraux D1 et traitement de la maladie de Parkinson
004411 O. Rascol [France] ; U. Sabatini [Italie] ; N. Fabre [France] ; C. Brefel [France] ; I. Loubinoux [France] ; P. Celsis [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; F. Chollet [France]The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients
004420 J. M. Senard [France] ; S. Rai [France] ; M. Lapeyre-Mestre [France] ; C. Brefel [France] ; O. Rascol [France] ; A. Rascol [France] ; J. L. Montastruc [France]Prevalence of orthostatic hypotension in Parkinson's disease
004437 J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France]Glutamate antagonists and Parkinson's disease : A review of clinical data
004475 J L Montastruc [France] ; O. Rascol ; J M SenardNew directions in the drug treatment of Parkinson's disease.
004484 J L Montastruc [France] ; J M Senard ; O. Rascol ; A. RascolAutonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences.
004486 O. Rascol [France] ; A J Lees ; J M Senard ; Z. Pirtosek ; C. Brefel ; J L Montastruc ; D. FuellA placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
004661 O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. FuellRopinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
004682 M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France]A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients
004692 J L Montastruc [France] ; O. Rascol ; J M Senard ; G. Houin ; A. RascolSublingual apomorphine: a new pharmacological approach in Parkinson's disease?
004699 J M Sénard [France] ; P. Verwaerde ; O. Rascol ; J L MontastrucEffects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians.
004900 O. Rascol [France] ; U. Sabatini ; N. Fabre [France] ; J. M. Senard [France] ; M. Simonetta-Moreau [France] ; J. L. Montrastruc [France] ; M. Clanet [France] ; A. Rascol [France]Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
004912 M E Llau [France] ; L. Nguyen ; J M Senard ; O. Rascol ; J L Montastruc[Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance].
004942 O. Blin [France] ; C. Desnuelle [France] ; O. Rascol [France] ; M. Borg [France] ; H. Peyro Saint Paul [France] ; J. P. Azulay [France] ; F. Billé [France] ; D. Figarella [France] ; F. Coulom [France] ; J. F. Pellissier [France] ; J. L. Montastruc [France] ; M. Chatel [France] ; G. Serratrice [France]Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy
004A02 O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J M Senard [France] ; J L Montastruc [France] ; P. Celsis [France] ; J P Marc-Vergnes [France] ; A. Rascol [France]Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
004A26 Jl Montastruc [France] ; Me Llau [France] ; O. Rascol [France] ; Jm Senard [France]Drug‐induced parkinsonism: a review
004A44 J L Montastruc [France] ; O. Rascol [France] ; J M Senard [France] ; A. Rascol [France]A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
004A78 O. Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. RascolNaltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
004A80 H. Bagheri [France] ; M. Berlan ; J. M. Senard ; O. Rascol ; J. L. MontastrucLacrimation in Parkinson's disease
004A93 J.-F. Demonet [France] ; P. Celsis [France] ; A. Agniel [France] ; D. Cardebat [France] ; O. Rascol [France] ; J.-P. Marc-Vegnes [France]Activation of regional cerebral blood flow by a memorization task in early Parkinson's disease patients and normal subjects
004C26 J. M. Senard [France] ; O. Rascol [France] ; B. Chamontin [France] ; A. Rascol [France] ; J.-L. Montastruc [France]Enregistrement ambulatoire de la pression artérielle dans l'hypotension orthostatique de la maladie de Parkinson
004C51 J. M. Senard [France] ; O. Rascol [France] ; A. Rascol ; J. L. Montastruc [France]Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension
004C61 J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. MontastrucEffects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy
004C65 J. L. Montastruc [France] ; O. Rascol ; J. M. SenardCurrent status of dopamine agonists in Parkinson's disease management
004C70 N. Fabre [France] ; J. L. Montastruc ; O. RascolAlopecia : an adverse effect of bromocriptine
004E33 O. Rascol [France] ; U. Sabatini ; F. Chollet ; P. Celsis ; J.-L. Montastruc ; J.-P. Marc-Vergnes ; A. RascolSupplementary and primary sensory motor area activity in Parkinson's disease : regional cerebral blood flow changes during finger movements and effects of apomorphine
004E38 A. Kastner [France] ; E. C. Hirsch ; O. Lejeune ; F. Javoy-Agid ; O. Rascol [France] ; Yves Agid [France]Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content ?
004E51 J L Montastruc [France] ; O. Rascol ; J M Senard ; V. Gualano ; H. Bagheri ; G. Houin ; A. Lees ; A. RascolSublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
004F52 A. Agniel [France] ; P. Celsis [France] ; G. Viallard [France] ; J L Montastruc [France] ; O. Rascol [France] ; J F Demonet [France] ; J P Marc-Vergnes [France] ; A. Rascol [France]Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries.
004F89 J. L. Montrastuc [France] ; O. Rascol ; J. M. Senard ; V. Gualano ; H. Bagheri ; G. Houin ; A. Lees ; A. RascolSublingual apomorphine in Parkinson's disease : a clinical and pharmacokinetic study
004F90 U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. MontastrucSubcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms
004F91 O. Rascol [France] ; U. Sabatini ; SIMONETTA-MOREAU ; J. L. Montastruc ; A. Rascol ; M. ClanetSquare wave jerks in Parkinsonian syndromes
005011 G. Durrieu [France] ; J M Senard ; O. Rascol ; M A Tran ; X. Lataste ; A. Rascol ; J L MontastrucBlood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243).
005036 U. Sabatini [France] ; O. Rascol [France] ; P. Celsis [France] ; J. P. Marc-Vergnes [France] ; J. L. Montastruc [France]Effects of apomorphine on cerebral blood flow and extrapyramidal symptoms in Parkinson's disease
005117 J.-L. Montastruc [France] ; O. Rascol ; J.-M. SenardLes médicaments anti-parkinsoniens : bilan et nouvelles perpectives pharmacologiques
005127 J. L. Montastruc ; O. Rascol ; A. RascolComparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée
005136 U. Sabatini ; O. Rascol ; A. Rascol ; J.-L. MontastrucMigraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients
005141 O. Rascol ; N. Fabre ; H. Teraêvaêinen ; Werner Poewe [Autriche] ; C. Luêcking ; U. Rinne ; E. Dupont ; D. Hirt ; M. Hoyer ; X. LatasteCQA 206-291 : a novel dopamine agonist in the treatment of Parkinson's disease
005156 M. Berlan [France] ; O. Rascol ; J. Belin ; J P Moatti ; A. Rascol ; J L MontastrucAlpha 2-adrenergic sensitivity in Parkinson's disease.
005182 O. Rascol [France] ; M. Clanet [France] ; J. L. Montastruc [France] ; M. Simonetta [France] ; M. J. Soulier-Esteve [France] ; B. Doyon [France] ; A. Rascol [France]ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE
005219 J L Montastruc [France] ; O. Rascol [France] ; A. Rascol [France]A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
005244 M. Berlan ; O. Rascol ; J. Belin ; J.-P. Moatti ; A. Rascol ; J.-L. Montastrucα2-Adrenergic sensitivity in Parkinson's disease
005331 J.-P. Marc-Vergnes ; P. Celsis ; J. L. Montastruc ; J. F. Demonet ; A. Agniel ; O. Rascol ; G. Viallard ; B. Doyon ; A. RascolHémodynamique cérébrale et pharmacologie clinique dans la maladie de Parkinson
005332 P. Celsis ; O. Rascol ; J. F. Demonet ; A. Agniel ; J. L. Montastruc ; J. P. Marc-Vergnes ; A. RascolEffet de la bromocriptine sur le débit sanguin cérébral dans la maladies de Parkinson
005334 J. L. Montastruc ; O. Rascol ; A. RascolBromocriptine versus levodopa dans le traitement de première intention de la maladie de Parkinson. Premiers résultats à deux ans
005335 O. Rascol ; J. L. Montastruc ; J. M. Senard ; J. F. Demonet ; M. Simonetta ; A. RascolTwo weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial
005420 J. L. Montastruc ; O. Rascol ; J. Belin ; M. Ane ; A. RascolDoes papaverine interact with levodopa in Parkinson's disease?
005479 A. Rascol ; J. L. Montastruc ; O. Rascol ; J. M. SenardMesulergine (CU 32-085) in the treatment of Parkinson's disease
005926 O. Rascol [France] ; C. Brefel-Courbon ; O. Blin[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
005928 C. Soubrouillard [France] ; C. Lombardo ; O. Rascol ; B. Bruguerolle ; O. Blin[Central dopaminergic D1 agonists and treatment of Parkinson disease].
005945 J L Montastruc [France] ; C. Brefel-Courbon ; J M Senard ; H. Bagheri ; J. Ferreira ; O. Rascol ; M. Lapeyre-MestreSleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.
005952 O. Rascol [France] ; D J Brooks ; E. Melamed ; W. Oertel ; Werner Poewe ; F. Stocchi ; E. TolosaRasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
005A11 H. Bagheri [France] ; C. Damase-Michel ; M. Lapeyre-Mestre ; S. Cismondo ; D. O'Connell ; J M Senard ; O. Rascol ; J L MontastrucA study of salivary secretion in Parkinson's disease.

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024